Mounjaro Cost 2026: What You'll Pay Without Insurance
Complete Mounjaro cost breakdown for 2026: monthly pricing by dose, annual expenses, insurance coverage rules, savings-card eligibility, and discount-card limits.
Written by Trimi Medical Team. Medically reviewed by Dr. Sean Arora, MD. Pricing data is sourced from pharmacy surveys, manufacturer information, and market analysis updated regularly.
Quick links: Semaglutide treatment, tirzepatide treatment, and best GLP-1 provider guide.
More on GLP-1 Provider Comparisons
Mounjaro Pricing Overview for 2026
Mounjaro (tirzepatide) has established itself as one of the most effective medications for both type 2 diabetes management and weight loss. Manufactured by Eli Lilly, Mounjaro's dual GIP/GLP-1 receptor agonist mechanism produces remarkable clinical results. However, those results come with a price tag that places the medication out of reach for many patients without comprehensive insurance coverage.
In 2026, Mounjaro's retail price without insurance remains in the range of $1,000 to $1,200 per month. Like most brand-name GLP-1 medications, the price is consistent across dose levels, patients pay the same whether they are on the 2.5mg starting dose or the 15mg maximum dose. This pricing structure means that patients in the early titration phase pay premium prices for doses that contain significantly less active ingredient than they will eventually use at maintenance.
The annual cost of Mounjaro at retail pricing, $12,000 to $14,400, represents a significant financial commitment that exceeds the budget of most American households for a single medication. That is why coverage, prior authorization, and manufacturer program eligibility matter so much for anyone starting tirzepatide.
Dose-by-Dose Pricing Breakdown
| Dose Level | Treatment Phase | Mounjaro Retail | Notes |
|---|---|---|---|
| 2.5mg weekly | Weeks 1-4 | ~$1,050/mo | Starting dose; same list price as maintenance |
| 5mg weekly | Weeks 5-8 | ~$1,050/mo | First titration step |
| 7.5mg weekly | Weeks 9-12 | ~$1,050/mo | Second titration step |
| 10mg weekly | Weeks 13-16 | ~$1,050/mo | Third titration step |
| 12.5mg weekly | Weeks 17-20 | ~$1,050/mo | Fourth titration step |
| 15mg weekly | Maintenance | ~$1,050/mo | Maximum labeled dose |
The list price does not move as you titrate, which means the 2.5mg starting dose and the 15mg maintenance dose carry the same monthly cost even though they contain very different amounts of active ingredient. For a broader look at how tirzepatide is priced across providers, see our cost guide.
Insurance Coverage Landscape
Insurance coverage for Mounjaro is complicated by its FDA-approved indication. As a diabetes medication, Mounjaro generally has better insurance coverage than Wegovy or Zepbound when prescribed for type 2 diabetes. However, many patients seeking Mounjaro for weight loss are using it off-label, and insurance coverage for off-label weight loss use is significantly more limited.
Type 2 diabetes patients generally have better coverage prospects, though prior authorization is still common
Off-label weight loss use is often denied or restricted by insurance plans
Even covered patients may face specialty tier copays ranging from $100 to $500 per month
Prior authorization processes can delay treatment initiation by weeks
Some plans impose step therapy requiring failure of cheaper medications first
Coverage can vary dramatically between plans from the same insurer
The unpredictability of insurance coverage is a significant frustration for patients. Many start the process expecting coverage, invest weeks in prior authorization, and then receive a denial that sends them back to square one. Compounded tirzepatide bypasses this entirely, no insurance needed, no prior authorization, no denials, and predictable monthly pricing from day one.
Savings Strategies for Mounjaro
Patients committed to brand-name Mounjaro have several potential strategies for reducing what they pay out of pocket, and it is worth working through all of them with your prescriber's office before giving up on coverage.
The Eli Lilly savings card is the most commonly discussed option. When it works, it can reduce copays substantially for commercially insured patients. However, the savings card requires commercial insurance as a prerequisite, has a maximum benefit cap, and expires. Patients on Medicare, Medicaid, or without insurance are ineligible. For a detailed comparison, see our analysis of the Mounjaro savings card versus compounded tirzepatide.
Patient assistance programs, GoodRx coupons, and pharmacy discount cards can provide some savings but rarely bring Mounjaro's cost below $800 per month for uninsured patients. LillyDirect, Eli Lilly's own self-pay channel, is generally the more productive place for an uninsured patient to start.
What Goes Into Mounjaro's List Price
Patients frequently ask why a brand-name GLP-1 carries a four-figure monthly list price when the molecule itself has been characterized for years. The answer is about what the price is recovering, not about the molecule.
Eli Lilly invested billions in developing tirzepatide, conducting the extensive clinical trial program needed for FDA approval, building dedicated manufacturing facilities, and marketing the product globally. These costs are legitimate business expenses that are built into Mounjaro's retail price and recovered across the patent period.
List prices are also set with expected pharmacy benefit manager rebates and manufacturer discounts already factored in. An insured patient's plan captures some of those discounts; a cash-pay patient generally does not, which is why the sticker price and the negotiated net price diverge so widely.
The clinical trial program behind an FDA approval runs into the hundreds of millions of dollars
Dedicated FDA-registered manufacturing capacity is built years before a launch
Direct-to-consumer advertising and sales-force spend are recovered in the list price
Patent protection means there is no generic competition to pull the price down
Rebate expectations inflate the list price relative to what most plans actually pay
Bottom Line
Mounjaro is an exceptional medication with a large evidence base behind it. But at $1,000 to $1,200 per month without insurance, sustaining it long enough to get the outcomes seen in the trials is a real problem for uninsured patients. Work the coverage question first: prior authorization, the diabetes indication if it applies to you, the manufacturer savings card, and LillyDirect.
If a compounded preparation is what you and your clinician decide on, Trimi dispenses compounded tirzepatide at a flat $125 per month with licensed providers specializing in GLP-1 weight management, named 503A pharmacy partners, and month-to-month billing. Compounded tirzepatide is prepared per individual prescription and is not FDA-approved as a drug.
Frequently Asked Questions
How much does Mounjaro cost per month without insurance?
Mounjaro's retail price without insurance ranges from approximately $1,000 to $1,200 per month in 2026. This price is consistent across all available dose levels, from the 2.5mg starting dose through the 15mg maximum dose. Over a full year of treatment, patients paying out of pocket can expect to spend $12,000 to $14,400 for brand-name Mounjaro. Eli Lilly's savings card and LillyDirect self-pay program can change that figure for patients who qualify.
Does insurance cover Mounjaro for weight loss?
Insurance coverage for Mounjaro when used for weight loss is limited. Mounjaro is FDA-approved only for type 2 diabetes, so using it for weight loss is considered off-label. Many insurance plans restrict or deny coverage for off-label use. Patients with type 2 diabetes generally have better coverage prospects, but even then, prior authorization requirements and formulary restrictions are common. For dedicated weight loss coverage, Eli Lilly's separate brand Zepbound has a weight-specific FDA approval, though coverage is still inconsistent.
Is the Mounjaro savings card worth it?
The Mounjaro savings card from Eli Lilly can reduce costs for eligible patients, but has significant restrictions. It typically requires commercial insurance coverage, meaning uninsured patients cannot participate. The card has a maximum monthly benefit cap and an expiration date. For patients who qualify, it can reduce copays to as low as $25 per month, but not all patients meet the eligibility criteria. If you have commercial coverage, it is worth checking eligibility before assuming the card will not apply to you.
What are the cash-pay routes to tirzepatide in 2026?
There are three. Insurance coverage for brand-name Mounjaro or Zepbound, if your plan allows it. Eli Lilly's own self-pay channel and savings card, subject to their eligibility rules. Or a compounded tirzepatide prescription through a telehealth provider such as Trimi, which is a flat $125/month cash-pay rate. Compounded tirzepatide is prepared per individual prescription by a licensed pharmacy and is not FDA-approved as a drug, so which route is appropriate is a decision for your clinician.
Will Mounjaro get cheaper in 2026?
There is no indication that Eli Lilly plans to significantly reduce Mounjaro's retail price in 2026. Pharmaceutical pricing trends in the US have generally moved upward rather than downward for brand-name medications under patent protection. While external pressures from government negotiations and market competition may influence future pricing, patients should not count on significant retail price reductions in the near term. The practical levers remain coverage, prior authorization, the manufacturer savings card, and LillyDirect eligibility.
How does Mounjaro cost compare to other weight loss medications?
Mounjaro is among the more expensive GLP-1 medications at retail pricing. Wegovy costs approximately $1,300 to $1,500 per month, Zepbound approximately $1,060 per month, and Ozempic approximately $900 to $1,100 per month. These are list prices; what an insured patient actually pays depends on the plan, the tier, and whether a manufacturer savings card applies.
Can I use GoodRx or discount cards for Mounjaro?
GoodRx and similar prescription discount platforms can provide some savings on Mounjaro, but the discounts are typically modest compared to the retail price. Even with discount cards, patients often face costs of $800 to $1,000 per month. These cards are not insurance and do not provide the same level of savings that manufacturer savings cards or insurance coverage might offer. If you are uninsured, check LillyDirect and the manufacturer's own programs before relying on a discount card.
Sources & References
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Pricing information is based on publicly available data and may vary. Always verify current pricing directly with providers and pharmacies. Trimi offers compounded tirzepatide as an alternative, readers should be aware of our perspective.